Joline Si Jing Lim
National University Hospital, Singapore
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joline Si Jing Lim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:25 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04520269 · A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)National University Hospital, Singapore · active not recruiting · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:25 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.Cancer Discov · 2020115 citationsRCR 4.4
- Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.Clin Cancer Res · 202061 citationsRCR 2.2
- Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.J Transl Med · 201552 citationsRCR 1.4
- Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.Ann Surg Oncol · 202240 citationsRCR 3.1
- 33 citationsRCR 7.8
- Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.Clin Cancer Res · 202215 citationsRCR 0.8
- A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.Target Oncol · 202314 citationsRCR 1.2
- A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.BMC Cancer · 20207 citationsRCR 0.3
- Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.Target Oncol · 20225 citationsRCR 0.3
- Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.Br J Cancer · 20233 citationsRCR 0.2